Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

Sponsor

Transport Pharmaceuticals (Industry)

Overall Status

Completed

CT.gov ID

NCT00469300

Collaborator

(none)

810

Enrollment

Locations

Duration (Months)

62.3

Patients Per Site

10.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Currently approved drugs for the treatment of herpes labialis (cold sores) exhibit low levels of efficacy due to the limited ability of the drugs to penetrate the skin to the sites where the herpes virus is replicating. Iontophoresis uses electric current to enhance delivery of drugs through the skin. This trial is testing a new iontophoretic device with a new acyclovir gel to treat cold sores.

Condition or Disease	Intervention/Treatment	Phase
Herpes Labialis	Drug: Iontophoretic delivery of acyclovir	Phase 2

Detailed Description

This is a multicenter, placebo controlled, randomized, double blind, subject initiated study of the safety and efficacy of a single, 10-minute, topical iontophoretic application of a novel acyclovir 5% gel for the episodic treatment of recurrent herpes labialis. The design of the trial will also allow the comparison of the efficacy of a single iontophoretic treatment with acyclovir gel within 1 hour of first signs and/or symptoms of a herpetic episode to the efficacy of a single iontophoretic treatment with acyclovir gel 6 to18 hours after first signs and/or symptoms. Approximately 810 subjects will be enrolled to treat about 80 subjects in each of three treatment arms. Depending upon how the subject has been randomized into the trial, the subject will receive either: 1) an iontophoretic treatment with active gel within 1 hour of first signs/and or symptoms, followed 6-18 hours later by a second treatment with placebo gel; 2) an iontophoretic treatment with placebo gel within 1 hour of first signs/and or symptoms, followed 6-18 hours later by a second treatment with active gel; or 3) an iontophoretic treatment with placebo gel within 1 hour of first signs/and or symptoms, followed 6-18 hours later by a second treatment with placebo gel. After being enrolled and randomized into the study, subjects will be sent home with a locked kit containing the iontophoretic device with either active or placebo gel. At first signs and/or symptoms of a recurrent herpetic episode (prodromal or erythema), the lesion will be confirmed by telephone interview with the subject and, upon confirmation of the lesion, the subject will be given the combination to the locked kit and instructed to begin treatment immediately. The subject will then be instructed to return to the clinic within 6 to 18 hours of first signs and/or symptoms for a second iontophoretic treatment, appropriate to the treatment arm into which they have been randomized, and an evaluation. The subject will visit the clinic for daily follow-up evaluations for 3 to 14 days following the first treatment and will be called 2 weeks after their last clinic visit for a final safety evaluation.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

810 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

Double

Primary Purpose:

Treatment

Official Title:

A Multicenter, Placebo Controlled, Randomized, Double Blind, Subject Initiated Study of the Safety and Efficacy of the Electrokinetic Transdermal System (ETS) With Acyclovir Gel for the Episodic Treatment of Herpes Labialis

Study Start Date :

Apr 1, 2007

Actual Primary Completion Date :

Sep 1, 2007

Actual Study Completion Date :

Oct 1, 2007

Outcome Measures

Primary Outcome Measures

Clinician assessed duration of the herpetic episode measured from the time of treatment until the lesion is healed. [Lesion assessments for a minimum of 3 consecutive days and a maximum of 14 days.]

Secondary Outcome Measures

Clinician assessed: Prevention of progression to a classical lesion;Duration of classical herpetic lesions; Duration of herpetic lesions; Duration of the herpetic lesion hard scab; Duration until complete healing of the herpetic episode; [Lesion assessment for a minimum of 3 consecutive days and a maximum of 14 consecutive days.]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 75 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Male or female subject 18-75 years of age
Female subjects must be using a medically acceptable form of birth control during the study.
Subject must have a history of recurrent herpes labialis and report at least 3 recurrences during the preceding 12 months.
Subject must provide voluntary written informed consent to participate in this study.

Exclusion Criteria:

Subjects with a pacemaker, a history of cardiac arrhythmias or conduction abnormalities.
Any evidence of active malignancy or immunodeficient disease within the last 30 days. Subjects who have completed therapy and are considered unlikely to relapse or who have had surgery and do not have any evidence of disease, are eligible for the study.
Subject requires chronic use of immunomodifying drugs (e.g. systemic steroids) or topical steroids on or near the face; use of inhaled steroids does not exclude a subject from the study.
Subject requires chronic use of anti-viral medication.
History of allergic or adverse response to acyclovir, or any related anti-viral drug, or the gel base.
In females of childbearing potential, a positive urine pregnancy test at time of screening.
Nursing mothers.
Subjects with an implantable electronic device.
Subject has any body piercing in or around the area ordinarily affected by cold sores.
Subject is considered unreliable or unable to understand or follow the protocol directions or is unable to comprehend or satisfactorily assess a herpetic lesion as determined by Investigator or designee at screening.
Subject has abnormal skin conditions (e.g. acne, eczema, psoriasis, albinism, or chronic vesiculobullous disorders) that occur in the area ordinarily affected by cold sores or has significant facial hair in the area of the cold sore that might affect the normal course of the cold sore or might impair accurate evaluation of the cold sore lesion.
Subject has had an infection with HSV-1 isolates know to be resistant to acyclovir, valacyclovir, famciclovir, or ganciclovir.
Subject has had a herpes vaccine.
Subject is currently enrolled in another clinical trial involving the use of a drug and/or a device.
Subject has previously participated in the current study (TPI-H-221).
Subject requires chronic use of analgesics, pain medication or non-steroidal anti-inflammatory agents (NSAIDs).
Subject has a recent history of renal dysfunction or serious hepatic disease.
Subject has a history of alcoholism or drug abuse within the preceding 12 months.
Subject shares a household with another subject already enrolled in the study (TPI-H-221). If the other household member has already completed the study, then the currently enrolling subject is not excluded.
Subject is institutionalized.
Any history which, in the Investigator's judgment, makes the subject ineligible or places the subject at undue risk.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Radiant Research Birmingham	Birmingham	Alabama	United States	35209
2	Radiant Research Santa Rosa	Santa Rosa	California	United States	95405
3	Radiant Research St. Petersburg	Pinellas Park	Florida	United States	33781
4	Radiant Research Chicago	Chicago	Illinois	United States	60610
5	Radiant Research Minneapolis	Edina	Minnesota	United States	55435
6	Radiant Research St. Louis	St. Louis	Missouri	United States	63141
7	Rochester Clinical Research, Inc.	Rochester	New York	United States	14609
8	Radiant Research Cincinnati	Cincinnati	Ohio	United States	45236
9	Radiant Research Akron	Mogadore	Ohio	United States	44260
10	OMEGA Medical Research	Warwick	Rhode Island	United States	02886
11	Radiant Research Greer	Greer	South Carolina	United States	29651
12	Radiant Research Dallas North	Dallas	Texas	United States	75231
13	Radiant Research San Antonio	San Antonio	Texas	United States	78229